Skip to main content
. 2023 Sep 29;11:1179531. doi: 10.3389/fpubh.2023.1179531

Figure 2.

Figure 2

Networks of studies. Evidence network of all DAA-based regimens studied in end-stage renal disease patients with HCV infection. The thickness of the lines represents the number of studies (connecting lines) or the total number of patients studied (box lines). Within the box, the DAA combinations with the number of studies and number of patients are visible. ASV, asunaprevir; DCV, daclatasvir; DSV, dasabuvir; G/P, glecaprevir/pibrentasvir; GZR/EBR, grazoprevir-elbasvir; LDV, ledipasvir; OBV, ombitasvir; PTV/R, paritaprevir/ritonavir; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir.